Deadline: 9-Apr-25
The Product Development Award (PDA) general call seeks proposals aimed at developing new or improved vaccines, diagnostics, therapeutics, and biologics as global public goods for prevention and control of infectious diseases that disproportionately affect populations in low- and middle-income countries (LMICs).
The RIGHT Foundation is a Korean non-profit organization supported by the Korean Ministry of Health and Welfare, Korean life science companies, and the Bill & Melinda Gates Foundation. RIGHT Foundation aims to alleviate the burden of infectious diseases that disproportionately affect the people in low and middle-income countries.
The Product Development Award (PDA) aims to support efforts to develop and make available essential vaccines, therapeutics/biologics and diagnostics (VTDs) as global public goods. Investments in product development of VTDs are vital for reducing disease burden and alleviating suffering from infectious diseases. Vaccines, among the most cost-effective interventions, prevent millions of deaths annually.
Diagnostics play a crucial role in timely detection and management of diseases, advancing innovative approaches to improve surveillance and outbreak control. Ongoing therapeutics research focuses on combating drug-resistant strains and neglected diseases, ensuring that treatments are accessible to underserved populations.
Objectives
- This RFP seeks to support a broad range of efforts to develop and make available vaccines, diagnostics, therapeutics, and biologics that can significantly improve effectiveness, safety, or access across regions.
Funding Information
- Award amount: Up to 4 billion Korean won per project
Funding Scope
- Vaccines
- Therapeutics/ Biologics
- Diagnostics
- Technology Transfer
- Access enabling Research
Duration
- Up to 36 months
Eligibility Criteria
- Partnership requirement
- The applicant team must include at least one Korean entity with R&D expertise to make a significant contribution to the project. Inclusion of researchers, developers or advisors from the LMICs as the Principal Investigator or a collaborator is highly preferred.
- Eligible entities for Korean or international partners:
- For-profit companies engaged in life science or healthcare
- Non-profit research organizations and foundations
- Government research institutions
- Academic institutions
- Public health laboratories
Ineligibility Criteria
- They will not consider funding for:
- Early-stage discovery-phase proposals to generate pre-clinical candidates
- Basic research studies to improve understanding of pathogens, infections or disease
- Proposals without any data to support the proof of principle
- Proposals for setting up research facilities or capital equipment
- Duplicate technologies without a substantive advantage over the current best practice
- Concepts without a clear hypothesis or rationale for improved efficacy, potency, safety and/or ease of use over the current tools in clinical use or tools currently in development.
For more information, visit RIGHT Foundation.